A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma

(2020) Dilan A. Patel et al.   BONE MARROW TRANSPLANTATION

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients

(2019) Thierry Facon et al.   BLOOD

Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study

(2019) Theresa E. Hahn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis

(2019) Hanqing Li et al.   ANNALS OF HEMATOLOGY

Imaging and Bone Marrow Assessments Improve Minimal Residual Disease Prediction in Multiple Myeloma

(2019) Rafael Alonso et al.   AMERICAN JOURNAL OF HEMATOLOGY

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

(2019) Nizar Bahlis et al.   BLOOD

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

(2019) Takeshi Yoroidaka et al.   BLOOD

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

(2019) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

(2018) Sarah A. Holstein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy

(2018) C. Amos Clark et al.   BONE MARROW TRANSPLANTATION

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal Flow Cytometry Identified “Minimal Residual Disease” (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma

(2018) Jingli Gu et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

(2018) Meletios A. Dimopoulos et al.   HAEMATOLOGICA

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes

(2018) Bei Hu et al.   LEUKEMIA & LYMPHOMA

A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses

(2018) Dean Langan et al.   Research Synthesis Methods

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

(2018) Manuela Gambella et al.   CANCER

Minimal residual disease and log‐reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma

(2018) Giovanni Rossi et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

(2018) Graham H Jackson et al.   LANCET ONCOLOGY

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma

(2018) L. Rasche et al.   LEUKEMIA

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

(2017) Philip L. McCarthy et al.   JOURNAL OF CLINICAL ONCOLOGY

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

(2017) J Martinez-Lopez et al.   LEUKEMIA

High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

(2017) J R Mills et al.   Blood Cancer Journal

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

(2016) O Landgren et al.   BONE MARROW TRANSPLANTATION

Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response

(2016) Kota Fukumoto et al.   LEUKEMIA & LYMPHOMA

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

(2015) Heinz Ludwig et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple Myeloma, Version 2.2016

(2015) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

(2015) Neha Korde et al.   JAMA Oncology

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

(2014) M.-V. Mateos et al.   BLOOD

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

(2014) B. Paiva et al.   HAEMATOLOGICA

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

(2014) S Ferrero et al.   LEUKEMIA

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

(2014) R Silvennoinen et al.   Blood Cancer Journal

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter

(2011) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma

(2010) Mervi Putkonen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response

(2008) Pilar Martínez-Sánchez et al.   BRITISH JOURNAL OF HAEMATOLOGY